STOCK TITAN

Adaptive Biotechnologies (ADPT) shareholders back directors, pay and 2026 auditor

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Adaptive Biotechnologies Corporation reported the results of its annual shareholder meeting held on June 5, 2026. Shareholders voted on electing two Class I directors, an advisory say-on-pay proposal, and ratifying the independent auditor.

Robert Hershberg received 93,188,652 votes for, or 71.81% of votes on the proposal, with 36,573,708 votes withheld and 13,570,859 broker non-votes. Katey Owen received 126,803,695 votes for, or 97.72%, with 2,958,666 votes withheld and the same broker non-votes.

The advisory vote on 2025 named executive officer compensation passed with 125,287,618 votes for (96.55%), 4,316,144 against, and 158,599 abstentions, plus 13,570,859 broker non-votes. Ratification of Ernst & Young LLP as independent registered public accounting firm for 2026 passed with 142,609,643 votes for (99.50%), 484,798 against, and 238,779 abstentions.

Positive

  • None.

Negative

  • None.
Item 5.07 Submission of Matters to a Vote of Security Holders Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Hershberg votes for 93,188,652 votes Election of Class I director, 71.81% of proposal votes
Owen votes for 126,803,695 votes Election of Class I director, 97.72% of proposal votes
Say-on-pay votes for 125,287,618 votes Advisory vote on 2025 NEO compensation, 96.55% for
Auditor ratification votes for 142,609,643 votes Ratification of Ernst & Young LLP for 2026, 99.50% for
Say-on-pay votes against 4,316,144 votes Advisory vote on 2025 NEO compensation
Auditor votes against 484,798 votes Ratification of Ernst & Young LLP for 2026
Broker non-votes 13,570,859 votes Recorded on director and say-on-pay proposals
annual meeting of shareholders financial
"Adaptive Biotechnologies Corporation held its annual meeting of shareholders (the "Annual Meeting")"
A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.
Class I directors financial
"Proposal 1: election of two Class I directors to the Board of Directors"
Class I directors are the subset of a company’s board whose terms expire at a specific annual meeting under a staggered election system that divides directors into multiple groups with different re-election years. For investors this matters because staggered classes slow how quickly shareholders can replace the board, affecting takeover risk, governance change and the pace of corporate decisions — like rotating only part of a team instead of swapping everyone at once.
named executive officers financial
"advisory request concerning compensation for the Company's 2025 named executive officers"
Named executive officers are the senior company leaders whose names, roles and compensation are singled out in required regulatory filings; this typically includes the chief executive, chief financial officer and the next highest‑paid senior officers. Investors treat this list like a team roster — it shows who makes key decisions, how they are paid and whether incentives align with shareholder interests, so changes or pay patterns can signal governance quality, risk or strategic shifts.
independent registered public accounting firm financial
"ratification of Ernst & Young LLP as the Company's independent registered public accounting firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
broker non vote financial
"Broker Non Vote For | 93,188,652 | 71.81 % | 13,570,859"
When a broker holds shares for a client but does not have the client’s instructions to vote on a particular corporate matter, the broker often cannot cast a ballot; this is called a broker non-vote. It matters to investors because those uncast votes can change whether proposals pass, especially on important governance or merger issues, so active voting by investors can directly influence company decisions like a missing voice in a group vote.
emerging growth company financial
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false000147832000014783202026-06-052026-06-05

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 9, 2026 (June 05, 2026)

 

 

ADAPTIVE BIOTECHNOLOGIES CORPORATION

(Exact name of Registrant as Specified in Its Charter)

 

 

Washington

001-38957

27-0907024

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

1165 Eastlake Avenue East

 

Seattle, Washington

 

98109

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (206) 659-0067

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common stock, par value $0.0001 per share

 

ADPT

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 5, 2026, Adaptive Biotechnologies Corporation (the "Company") held its annual meeting of shareholders (the "Annual Meeting") pursuant to notice duly given. Three proposals were presented for voting: Proposal 1: election of two Class I directors to the Board of Directors (Robert Hershberg, PhD, MD and Katey Owen, PhD); Proposal 2: an advisory request concerning compensation for the Company's 2025 named executive officers; and, Proposal 3: ratification of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026. Each of the proposals was described in detail in the Company’s definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 24, 2026. A quorum of the shareholders voted by the conclusion of the Annual Meeting. The final results of the voting are set forth below.

 

Proposal 1: Election of Two Class I Directors

 

Robert Hershberg PhD, MD

Votes Submitted

As % of Proposal Votes

Broker Non Vote

For

93,188,652

71.81 %

13,570,859

Against

-

-

Withhold/Abstain

36,573,708

28.19 %

Katey Owen, PhD

Votes Submitted

As % of Proposal Votes

Broker Non Vote

For

126,803,695

97.72 %

13,570,859

 

Against

-

-

Withhold/Abstain

2,958,666

2.28 %

 

Proposal 2: Advisory Vote Concerning the 2025 Compensation of the Company's Named Executive Officers

 

Votes Submitted

As % of Proposal Votes

Broker Non Vote

For

125,287,618

96.55 %

13,570,859

Against

4,316,144

3.33 %

Withhold/Abstain

158,599

0.12 %

 

Proposal 3: Ramification of Ernst & Young LLP as the Company's Independent Registered Public Accounting Firm for the Year Ending December 31, 2026

 

Votes Submitted

As % of Proposal Votes

Broker Non Vote

For

142,609,643

99.50 %

0

Against

484,798

0.34 %

Withhold/Abstain

238,779

0.17 %

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Adaptive Biotechnologies Corporation

 

 

 

 

Date:

June 9, 2026

By:

/s/ Kyle Piskel

 

 

 

Kyle Piskel
Chief Financial Officer

 


FAQ

What did Adaptive Biotechnologies (ADPT) shareholders vote on at the 2026 annual meeting?

Shareholders voted on electing two Class I directors, approving 2025 named executive officer compensation in an advisory vote, and ratifying Ernst & Young LLP as the independent registered public accounting firm for the year ending December 31, 2026.

Were Adaptive Biotechnologies (ADPT) director nominees approved by shareholders?

Yes. Robert Hershberg received 93,188,652 votes for, or 71.81% of votes cast, while Katey Owen received 126,803,695 votes for, or 97.72%, along with 13,570,859 broker non-votes recorded for each director proposal.

How did Adaptive Biotechnologies (ADPT) shareholders vote on 2025 executive compensation?

Shareholders approved the advisory vote on 2025 named executive officer compensation with 125,287,618 votes for, representing 96.55% of votes cast, 4,316,144 votes against, 158,599 abstentions, and 13,570,859 broker non-votes recorded on the proposal.

Did Adaptive Biotechnologies (ADPT) shareholders ratify Ernst & Young as auditor?

Yes. Ernst & Young LLP was ratified as independent registered public accounting firm for 2026 with 142,609,643 votes for, or 99.50%, 484,798 votes against, and 238,779 votes marked as withhold or abstain on the auditor ratification proposal.

When did Adaptive Biotechnologies (ADPT) hold its 2026 annual shareholder meeting?

The company held its annual meeting of shareholders on June 5, 2026, pursuant to duly given notice. A quorum was present, and the meeting covered director elections, an advisory executive compensation vote, and auditor ratification for the 2026 fiscal year.

Filing Exhibits & Attachments

1 document